|
MAP9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.44849998662266E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.53479999995565E-07 |
| Normal-vs-Stage2 |
4.98919999980529E-07 |
| Normal-vs-Stage3 |
2.11639594738244E-11 |
| Normal-vs-Stage4 |
7.8115292012626E-13 |
| Stage1-vs-Stage2 |
6.774400E-01 |
| Stage1-vs-Stage3 |
4.515800E-02 |
| Stage1-vs-Stage4 |
3.760700E-03 |
| Stage2-vs-Stage3 |
1.604810E-01 |
| Stage2-vs-Stage4 |
2.831700E-02 |
| Stage3-vs-Stage4 |
2.362800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.04679994964386E-09 |
| Normal-vs-AfricanAmerican |
9.355500E-04 |
| Normal-vs-Asian |
7.53790030394441E-10 |
| Caucasian-vs-AfricanAmerican |
4.603200E-01 |
| Caucasian-vs-Asian |
2.267200E-01 |
| AfricanAmerican-vs-Asian |
1.121820E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.35318447955524E-12 |
| Normal-vs-Female |
4.11959999446765E-08 |
| Male-vs-Female |
1.593760E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.440760E-04 |
| Normal-vs-Age(41-60Yrs) |
3.60000917964953E-12 |
| Normal-vs-Age(61-80Yrs) |
2.89235302375346E-12 |
| Normal-vs-Age(81-100Yrs) |
6.935400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.452830E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.009950E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.752800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.102800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.199400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.715800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.142080E-02 |
| Classical-VS-Follicular |
2.622000E-01 |
| Classical-VS-Other |
1.414780E-01 |
| Classical-VS-Normal |
3.48149999940262E-08 |
| Tall-VS-Follicular |
1.338000E-03 |
| Tall-VS-Other |
7.435800E-01 |
| Tall-VS-Normal |
1.61549662536231E-11 |
| Follicular-VS-Other |
1.500390E-01 |
| Follicular-VS-Normal |
3.96999999999759E-05 |
| Other-VS-Normal |
4.608900E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.78634884662188E-13 |
| Normal-vs-N1 |
1.191810E-01 |
| N0-vs-N1 |
5.382000E-01 |
|
|
